Rare pediatric PRV program not linked to uptick in new drugs starting trials, study finds
The rare pediatric priority review voucher (PRV) program was not found to be associated with an increase in the number or rate of new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
